ClinicalTrials.gg
Not yet recruitingNCT07867327Updated Oct 9, 2026

A Study of LY4515100 in Healthy Male Participants

A Phase 1 interventional study of [¹⁴C]-LY4515100 Oral Solution and LY4515100 Tablet in Healthy, sponsored by Eli Lilly and Company. Not yet recruiting at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Updated Oct 9, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

The main purpose of this study is to evaluate how the body handles [¹⁴C]-LY4515100. The study will investigate how much [¹⁴C]-LY4515100 enters the bloodstream from the stomach or intestines and is available to have an effect on the body, how the body changes [¹⁴C]-LY4515100 so that it can be used or removed, and how the body gets rid of [¹⁴C]-LY4515100. For each participant, the study will last about 9 weeks and will include a Clinical Research Unit (CRU) stay lasting between 10 and 30 days.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are overtly healthy as determined by medical evaluation.
  • Have a (BMI) within the range of 18.0 to 35.0 kilograms per square meter (kg/m²), inclusive.

Exclusion criteria

Exclusion Criteria:

  • Have significant previous or current history of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinal, hematological, neurological, thromboembolism, or bleeding disorder capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study intervention; or of interfering with the interpretation of data.
  • Have a significant history of or current psychiatric disorders.
  • Have history of stomach or intestinal surgery or resection that would potentially alter absorption or excretion of orally administered drugs. Uncomplicated appendectomy and hernia repair will be allowed.
  • Have a history of constipation or have had acute constipation within 3 weeks prior to check-in.
  • Have had exposure to significant diagnostic, therapeutic, or employment-related radiation within 12 months prior to dosing, for example, serial x-ray or computed tomography scans, barium meal, or current employment in a job requiring radiation exposure monitoring.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
16 participants (estimated)

Study arms

  • Experimental
    [¹⁴C]-LY4515100 Part 1

    \[¹⁴C\]-LY4515100 containing radioactivity administered orally

    Drug: [¹⁴C]-LY4515100 Oral Solution

  • Experimental
    LY4515100 + [¹⁴C]-LY4515100 Part 2

    LY4515100 administered orally with \[¹⁴C\]-LY4515100 containing radioactivity administered intravenously (IV)

    Drug: LY4515100 Tablet · Drug: [¹⁴C]-LY4515100 IV

Interventions

  • Drug[¹⁴C]-LY4515100 Oral Solution

    \[¹⁴C\]-LY4515100 administered orally

  • LY4515100 administered orally

  • Drug[¹⁴C]-LY4515100 IV

    \[¹⁴C\]-LY4515100 administered IV

06

What researchers measure

Primary outcomes

  1. Part 1: Urinary Excretion of [¹⁴C]-LY4515100 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered

    Time frame: Predose Up to Day 14

  2. Part 1: Fecal Excretion of [¹⁴C]-LY4515100 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered

    Time frame: Predose Up to Day 14

  3. Part 2: Dose Normalized Ratio of the Area Under the Concentration-Time Curve After Oral Administration (AUCpo) to Area Under the Concentration-Time Curve After Intravenous Administration (AUCiv) of LY4515100

    Time frame: Predose Up to Day 14

Secondary outcomes

  1. Part 1: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from Time Zero to Infinity (AUC[0-inf]) of Total Plasma Radioactivity

    Time frame: Predose Up to Day 14

  2. Part 1: PK: Maximum Concentration (Cmax) of Total Plasma Radioactivity

    Time frame: Predose Up to Day 14

  3. Part 1: Total Radioactivity Recovered in Urine, Feces, and Expired Air

    Time frame: Predose Up to Day 14

  4. Part 1: Total Number of Metabolites of LY4515100 in Urine, Feces, and Plasma

    Time frame: Predose Up to Day 14

  5. Part 2: PK: Area Under the Concentration Versus Time Curve from Time Zero to Infinity (AUC[0-inf]) of [¹⁴C]-LY4515100

    Time frame: Predose Up to Day 9

  6. Part 2: PK: Maximum Concentration (Cmax) of [¹⁴C]-LY4515100

    Time frame: Predose Up to Day 9

  7. Part 2: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from Time Zero to Infinity (AUC[0-inf]) of Total Plasma Radioactivity

    Time frame: Predose Up to Day 9

  8. Part 2: PK: Maximum Concentration (Cmax) of Total Plasma Radioactivity

    Time frame: Predose Up to Day 9

07

Study locations

1 site
  • Fortrea Clinical Research Unit
    Madison, Wisconsin 53704, United States
    • · Contact608-442-8200
    • Kimberly Cruz · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Dec 2026, 2 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 5, 2026
First posted
Oct 9, 2026
StartEst.
Oct 2026
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07867327
Responsible party
Sponsor
First posted
Oct 9, 2026
Start date
Oct 2026 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Oct 9, 2026

Study contacts

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Contact
LillyTrials@Lilly.com
1-317-615-4559
Physicians interested in becoming principal investigators please contact
Contact
clinical_inquiry_hub@lilly.com
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: LY4515100

Start the discussion